Highly Conserved Interaction Profiles between Clinically Relevant Mutants of the Cytomegalovirus CDK-like Kinase pUL97 and Human Cyclins: Functional Significance of Cyclin H.
clinically relevant viral mutants
cyclin H functional significance
functional relevance
human cyclin complexes
human cytomegalovirus
kinase activity
mapping and knock-out analyses
pUL97/vCDK
pUL97–cyclin interaction
viral CDK-like kinase
viral replication efficiency
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
05 Oct 2022
05 Oct 2022
Historique:
received:
22
08
2022
revised:
28
09
2022
accepted:
29
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
The complex host interaction network of human cytomegalovirus (HCMV) involves the regulatory protein kinase pUL97, which represents a viral cyclin-dependent kinase (CDK) ortholog. pUL97 interacts with the three human cyclin types T1, H, and B1, whereby the binding region of cyclin T1 and the pUL97 oligomerization region were both assigned to amino acids 231-280. We further addressed the question of whether HCMVs harboring mutations in ORF-UL97, i.e., short deletions or resistance-conferring point mutations, are affected in the interaction with human cyclins and viral replication. To this end, clinically relevant UL97 drug-resistance-conferring mutants were analyzed by whole-genome sequencing and used for genetic marker transfer experiments. The recombinant HCMVs indicated conservation of pUL97-cyclin interaction, since all viral UL97 point mutants continued to interact with the analyzed cyclin types and exerted wild-type-like replication fitness. In comparison, recombinant HCMVs UL97 Δ231-280 and also the smaller deletion Δ236-275, but not Δ241-270, lost interaction with cyclins T1 and H, showed impaired replication efficiency, and also exhibited reduced kinase activity. Moreover, a cellular knock-out of cyclins B1 or T1 did not alter HCMV replication phenotypes or pUL97 kinase activity, possibly indicating alternative, compensatory pUL97-cyclin interactions. In contrast, however, cyclin H knock-out, similar to virus deletion mutants in the pUL97-cyclin H binding region, exhibited strong defective phenotypes of HCMV replication, as supported by reduced pUL97 kinase activity in a cyclin H-dependent coexpression setting. Thus, cyclin H proved to be a very relevant determinant of pUL97 kinase activity and viral replication efficiency. As a conclusion, the results provide evidence for the functional importance of pUL97-cyclin interaction. High selective pressure on the formation of pUL97-cyclin complexes was identified by the use of clinically relevant mutants.
Identifiants
pubmed: 36233116
pii: ijms231911814
doi: 10.3390/ijms231911814
pmc: PMC9569496
pii:
doi:
Substances chimiques
Amino Acids
0
Cyclin H
0
Cyclin T
0
Genetic Markers
0
Viral Proteins
0
pUL97 protein, cytomegalovirus
0
Phosphotransferases (Alcohol Group Acceptor)
EC 2.7.1.-
Cyclin-Dependent Kinases
EC 2.7.11.22
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Interdisciplinary Center of Clinical Research of the Medical Center/Universitätsklinikum Erlangen
ID : IZKF project A88-M.M./H.S.
Organisme : Matching Funds Program of the Forschungsstiftung Medizin, Medical Center UKER (Erlangen) together with the Manfred Roth-Stiftung (Fürth)
ID : grant M.M./Ma.S.
Organisme : Bayerische Forschungsstiftung
ID : grant DeeP CMV/AP-5/M.M.
Organisme : DAAD-Go8
ID : grants MM/WDR 2015-16, 2017-18, 2020-21
Références
Antimicrob Agents Chemother. 2015 Apr;59(4):2062-71
pubmed: 25624324
J Gen Virol. 2011 Mar;92(Pt 3):638-49
pubmed: 21084499
J Gen Virol. 2009 Mar;90(Pt 3):567-578
pubmed: 19218201
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Ital J Pediatr. 2017 Apr 17;43(1):38
pubmed: 28416012
Viruses. 2016 Aug 18;8(8):
pubmed: 27548200
Antimicrob Agents Chemother. 2000 Jun;44(6):1588-97
pubmed: 10817714
Antiviral Res. 2013 Aug;99(2):139-48
pubmed: 23648710
Semin Cell Dev Biol. 2020 Nov;107:28-35
pubmed: 32334991
J Biol Chem. 2019 Apr 12;294(15):6188-6203
pubmed: 30782840
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13585-90
pubmed: 14593199
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14223-8
pubmed: 14623981
Methods Mol Biol. 2010;634:421-30
pubmed: 20677001
Antimicrob Agents Chemother. 2011 Jan;55(1):382-4
pubmed: 21041510
J Gen Virol. 2016 Jan;97(1):144-151
pubmed: 26555090
J Virol. 2012 Sep;86(17):9369-83
pubmed: 22718829
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12396-401
pubmed: 14519856
Virus Evol. 2016 Jun 15;2(1):vew017
pubmed: 30288299
Biotechniques. 2008 Dec;45(6):659-62, 664-8
pubmed: 19238796
Viruses. 2020 Jun 24;12(6):
pubmed: 32599939
J Gen Virol. 2007 Feb;88(Pt 2):395-404
pubmed: 17251555
Viruses. 2021 Mar 12;13(3):
pubmed: 33809234
J Med Chem. 2006 Nov 30;49(24):7044-53
pubmed: 17125257
Science. 2008 May 9;320(5877):797-9
pubmed: 18467589
Viruses. 2020 Dec 24;13(1):
pubmed: 33374185
J Infect Dis. 2019 Jul 31;220(5):781-791
pubmed: 31050742
J Gen Virol. 2017 Nov;98(11):2850-2863
pubmed: 29022869
Lancet Infect Dis. 2017 Jun;17(6):e177-e188
pubmed: 28291720
Rev Med Virol. 2017 Jul;27(4):
pubmed: 28664574
Nat Biotechnol. 2013 Sep;31(9):827-32
pubmed: 23873081
Viruses. 2018 Aug 03;10(8):
pubmed: 30081496
J Gen Virol. 2008 Feb;89(Pt 2):359-368
pubmed: 18198366
J Clin Invest. 2010 Sep;120(9):3191-208
pubmed: 20679731
J Pathol. 2015 Jan;235(2):288-97
pubmed: 25205255
Microorganisms. 2020 Apr 04;8(4):
pubmed: 32260430
Viruses. 2015 Jun 05;7(6):2884-907
pubmed: 26057166
Genome Biol. 2014;15(6):122
pubmed: 25180339
Antiviral Res. 2018 Sep;157:128-133
pubmed: 30040968
Nature. 2003 Jul 10;424(6945):228-32
pubmed: 12853965
Anal Biochem. 2006 May 15;352(2):198-207
pubmed: 16600168
Viruses. 2018 Jan 13;10(1):
pubmed: 29342872
Viruses. 2021 Jun 27;13(7):
pubmed: 34198986
Viruses. 2015 Aug 11;7(8):4582-601
pubmed: 26270673
PLoS Pathog. 2007 Jan;3(1):e6
pubmed: 17206862
J Gen Virol. 2012 Aug;93(Pt 8):1756-1768
pubmed: 22552943
Proc Soc Exp Biol Med. 1956 Jun;92(2):418-24
pubmed: 13350367
Med Microbiol Immunol. 2015 Jun;204(3):273-84
pubmed: 25894764
Drugs. 2022 Feb;82(3):335-340
pubmed: 35147913
J Biol Chem. 2015 Aug 7;290(32):19666-80
pubmed: 26100623
Nat Commun. 2020 Sep 24;11(1):4845
pubmed: 32973148
Microorganisms. 2020 May 30;8(6):
pubmed: 32486127
Antiviral Res. 2020 Apr;176:104711
pubmed: 31940472
Antimicrob Agents Chemother. 2019 Aug 23;63(9):
pubmed: 31262766
Viruses. 2013 Dec 18;5(12):3213-30
pubmed: 24351800
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14976-81
pubmed: 14657367
J Gen Virol. 2017 Oct;98(10):2569-2581
pubmed: 28949903
Med Microbiol Immunol. 2015 Jun;204(3):409-19
pubmed: 25776080
Antiviral Res. 2016 Oct;134:130-143
pubmed: 27515131
Rev Med Virol. 2009 Jul;19(4):215-29
pubmed: 19434630
Microorganisms. 2020 Apr 25;8(5):
pubmed: 32344906
J Am Chem Soc. 2003 Nov 26;125(47):14248-9
pubmed: 14624552
Int J Mol Sci. 2021 Jan 08;22(2):
pubmed: 33430060
Mol Cell Proteomics. 2014 Aug;13(8):2132-46
pubmed: 24969177
Int J Mol Sci. 2022 Feb 24;23(5):
pubmed: 35269635
J Virol. 2008 Jan;82(1):394-407
pubmed: 17942543
Front Microbiol. 2016 Sep 09;7:1317
pubmed: 27667983
Antiviral Res. 2021 Sep;193:105139
pubmed: 34273445
Cell Cycle. 2005 Apr;4(4):572-7
pubmed: 15876871
ACS Chem Biol. 2015 Jan 16;10(1):175-89
pubmed: 25494294
J Biol Chem. 2017 Apr 21;292(16):6583-6599
pubmed: 28289097
Viruses. 2021 Mar 11;13(3):
pubmed: 33799898
Viruses. 2021 Jan 22;13(2):
pubmed: 33499341